RKTO on Nasdaq

Rocket One Inc.

American pharmaceutical preparations company based in New York.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

  • TickerRKTO on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersNV
  • Incorporated inNV2
  • Business address720 Monroe Street, Suite E514, Hoboken, Nj 070302
  • Filer categoryNon-accelerated filer, Smaller reporting company2

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income345678-$12.4M in 2025+60% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.7M-$7.7M20192020: -$7.3M-$7.3M2020−5%2021: -$14.1M-$14.1M2021+93%2022: -$11.1M-$11.1M2022−22%2023: -$8.0M-$8.0M2023−28%2024: -$8.2M-$8.2M2024+3%2025: -$12.4M-$12.4M2025+50%
Net income345678-$12.5M in 2025+62% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.7M-$7.7M20192020: -$7.2M-$7.2M2020−7%2021: -$14.3M-$14.3M2021+99%2022: -$11.4M-$11.4M2022−21%2023: -$8.1M-$8.1M2023−29%2024: -$8.2M-$8.2M2024+1%2025: -$12.5M-$12.5M2025+52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development expenses$5.9M$3.2M
General and administrative expenses$6.4M$5.0M
Total operating expenses$12.4M$8.2M
LOSS FROM OPERATIONS-$12.4M-$8.2M
Change in fair value of investment in joint venture-$581
Unrealized loss on crypto assets-$108.6K
Dividend and interest income$680$27.7K
Total other (expenses) income, net-$108.0K$27.1K
NET LOSS-$12.5M-$8.2M
Basic-$0.90-$1.28
Diluted-$0.90-$1.28
Basic13.8M shares6.4M shares
Diluted13.8M shares6.4M shares
Foreign currency translation adjustment$1.8K-$18.2K
Total comprehensive loss-$12.5M-$8.2M

Compare Rocket One Inc. with another company

Leadership

Who has led Rocket One Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robb Knie2019–now

Chief financial officer

  1. David S. Briones2019
20202025
Board members and other officers (9)

Former names

  • Hoth Therapeutics, Inc.Jul 14, 2017 to May 27, 20262

Timeline

  1. Feb 15, 2019New chief executive Robb Knie becomes CEO11

Filings

175 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 34 insider forms, 7 large holders, 1 private raises, 52 other. The latest 20:

  1. Oct 2, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  2. Sep 25, 20268-K CURRENT REPORT EDGAR
  3. Sep 22, 20268-K CURRENT REPORT EDGAR
  4. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  5. Aug 11, 20268-K CURRENT REPORT EDGAR
  6. Jul 31, 20268-K CURRENT REPORT EDGAR
  7. Jul 31, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  8. Jul 21, 20268-K CURRENT REPORT EDGAR
  9. Jun 25, 20268-K CURRENT REPORT EDGAR
  10. Jun 3, 20268-K CURRENT REPORT EDGAR
  11. Jun 3, 20268-K CURRENT REPORT EDGAR
  12. Jun 3, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  13. Jun 2, 20268-K CURRENT REPORT EDGAR
  14. May 28, 20264 EDGAR
  15. May 28, 20264 EDGAR
  16. May 28, 20264 EDGAR
  17. May 28, 20264 EDGAR
  18. May 28, 20264 EDGAR
  19. May 28, 20268-K CURRENT REPORT EDGAR
  20. May 27, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR

The 175 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 7 such filings since October 2021:

  1. Feb 14, 2024SC 13G/A
  2. Feb 14, 2023SC 13G
  3. Feb 8, 2023SC 13G/A
  4. Feb 23, 2022SC 13G/A
  5. Feb 11, 2022SC 13G/A
  6. Feb 9, 2022SC 13G/A
  7. Feb 3, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 3, 2023Raised $10 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC683,291$683.3K0.0%+553,600
Jane Street Group, LLC219,316$219.3K0.0%New
UBS Group AG211,304$211.3K0.0%+53,327
Geode Capital Management, LLC195,982$196.0K0.0%−18,262
Vanguard Fiduciary Trust Co84,318$84.3K0.0%No change
State Street Corp63,939$63.9K0.0%No change
LPL Financial LLC41,029$41.0K0.0%New
Northern Trust Corp38,724$38.7K0.0%−3,330
Susquehanna International Group, Llp25,966$26.0K0.0%New
Lido Advisors, LLC19,500$19.5K0.0%−19,500
Morgan Stanley10,006$10.0K0.0%No change
Charles Schwab Trust Co10,000$10.0K0.0%New
SBI Securities Co., Ltd.4,517$4.5K0.0%+4,506
Farther Finance Advisors, LLC4,237$4.2K0.0%New
Osaic Holdings, Inc.2,701$2.7K0.0%No change
Tower Research Capital LLC (TRC)2,005$2.0K0.0%−5,350
Federation des caisses Desjardins du Quebec350$3430.0%No change
Jones Financial Companies Lllp100$950.0%−400
Mcguire Capital Advisors Inc50$500.0%New
IFP Advisors, Inc45$450.0%No change
Royal Bank Of Canada240$00.0%−630

13F reports cover disclosed long positions in U.S. stocks only.